Anika Therapeutics, Inc. Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31)
Anika Therapeutics, Inc. (ANIK) reported Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) of $64.64 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-06.
Discontinued › Expense Statement › Income Tax
us-gaap:TaxBenefitFromStockOptionsExercised1 · last filed 2013-05-06
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $64.64K, a 83.60% decline year-over-year.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $4.33K.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$56.47K.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for the quarter ending 2012-06-30 was -$794.40K.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2012 was -$452.47K.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2011 was -$274.19K.
- Anika Therapeutics, Inc. tax benefit from stock options exercised (deprecated 2013-01-31) for fiscal 2010 was -$65.43K.
| Period end | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 3 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 6 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 9 month | Tax Benefit from Stock Options Exercised (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | $64.64K 10-Q · filed 2013-05-06 | $68.97K derived: sum of 2 quarters · filed 2013-05-06 | $12.50K derived: sum of 3 quarters · filed 2013-05-06 | -$781.90K derived: sum of 4 quarters · filed 2013-05-06 |
| 2012-12-31 | $4.33K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | -$52.15K derived: sum of 2 quarters · filed 2013-03-14 | -$846.55K derived: sum of 3 quarters · filed 2013-03-14 | -$452.47K 10-K · filed 2013-03-14 |
| 2012-09-30 | -$56.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$850.87K derived: sum of 2 quarters · filed 2012-11-08 | -$456.80K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | -$794.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$400.32K 10-Q · filed 2012-08-07 | ||
| 2012-03-31 | $394.08K 10-Q · filed 2013-05-06 | |||
| 2011-12-31 | -$274.19K 10-K · filed 2013-03-14 | |||
| 2010-12-31 | -$65.43K 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |